Company intelligence / Profile preview

Palette Life Sciences

Stockholm, Sweden

Ownership: Public · TFX
Development stage: Other

Overview

Deflux: FDA-approved injectable for pediatric vesicoureteral reflux. Solesta: FDA-approved injectable for fecal incontinence, also cleared in Europe. Barrigel: FDA-cleared since May 2022 for protecting rectal wall during prostate cancer radiotherapy, CE Marked, cleared in Australia.

Therapeutic areas: OncologyNephrologyGastroenterology
Modalities: DeviceBiologic
Industry: Biotech

Partnerships

Nestle Skin Health (licensed NASHA technology)Back Bay Life Science Advisors (strategic consulting/fundraising)

Beyond the preview

Go deeper on Palette Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Palette Life Sciences.

Explore the full profile